Journal article
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
- Abstract:
-
Objectives
Expand abstract
Respiratory syncytial virus (RSV) causes respiratory infection across the world, with infants and the elderly at particular risk of developing severe disease and death. The replication-defective chimpanzee adenovirus (PanAd3-RSV) and modified vaccinia virus Ankara (MVA-RSV) vaccines were shown to be safe and immunogenic in young healthy adults. Here we report an extension to this first-in-man vaccine trial to include healthy older adults aged 60–75 years.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 3.1MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.jinf.2019.02.003
Authors
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- Journal of Infection More from this journal
- Volume:
- 78
- Issue:
- 5
- Pages:
- 382-392
- Publication date:
- 2019-02-08
- Acceptance date:
- 2019-02-05
- DOI:
- EISSN:
-
1532-2742
- ISSN:
-
0163-4453
- Pmid:
-
30742894
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:971178
- UUID:
-
uuid:bf49a7bd-038b-447d-a0a7-a7c568c17269
- Local pid:
-
pubs:971178
- Source identifiers:
-
971178
- Deposit date:
-
2019-02-12
Terms of use
- Copyright holder:
- British Infection Association
- Copyright date:
- 2019
- Rights statement:
- © 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.jinf.2019.02.003
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record